Curevac partners with myneo to identify novel antigen targets for mrna-based cancer vaccine development

Curevac is broadening its foundation in oncology, leveraging recent progress with its second-generation mrna backbone the partnership combines curevac's mrna technology with myneo's platform for the discovery and selection of tumor antigens predicted to elicit strong immune responses together with myneo, curevac aims to identify specific antigens for the development of novel mrna cancer vaccines tÜbingen, germany and ghent, belgium / accesswire / may 25, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), and myneo n.v.
CVAC Ratings Summary
CVAC Quant Ranking